Ludwig Saskia, Theis Cathrin, Brown Ben, Witthohn Andreas, Lux Wolfram, Goette Andreas
HGC GesundheitsConsult GmbH, Duesseldorf, Germany.
Robert-Bosch-Krankenhaus, Zentrum für Innere Medizin III Kardiologie, Auerbachstraße 110, 70376 Stuttgart, Germany.
J Comp Eff Res. 2018 May;7(5):483-492. doi: 10.2217/cer-2017-0080. Epub 2017 Nov 14.
Estimate incidence and costs of cardiac device infections (CDIs) in Germany.
MATERIALS & METHODS: Patients had an implantable cardioverter defibrillator implanted over 2010-2013 and were followed to December 2014 using German health insurance claims data. A case-controlled analysis was performed using propensity score matching methods.
Risk of CDI 12 months post-implant was 3.4% overall, either 2.9% for de novo procedures versus 4.4% for replacement procedures. Mean 3-year incremental expenditure per patient for patients with CDI compared with controls was €31,493 for de novo implant patients and €33,777 for replacement patients. Mean incremental expenditure was €59,419 per patient with a major infection.
CDIs are highly expensive to manage, reinforcing the need for strategies to reduce their occurrence.
估算德国心脏设备感染（CDI）的发生率及成本。
患者于2010 - 2013年植入植入式心脏复律除颤器，并利用德国医疗保险理赔数据随访至2014年12月。采用倾向得分匹配法进行病例对照分析。
植入后12个月时CDI的总体风险为3.4%，其中初次植入手术的风险为2.9%，而更换手术的风险为4.4%。与对照组相比，CDI患者每位患者3年的平均增量支出，初次植入患者为31,493欧元，更换患者为33,777欧元。发生严重感染的患者每位患者的平均增量支出为59,419欧元。
CDI的管理成本高昂，这进一步凸显了减少其发生的策略的必要性。
